Andrés Dulcey is a research scientist in the Chemistry Technology program within NCATS’ Division of Preclinical Innovation, where he optimizes drug-like properties of small molecules identified through high-throughput screening collaboration programs and develops molecular probes used to investigate the pharmacological basis of disease. Before joining NCATS, Dulcey served as a postdoctoral fellow at the Eunice Kennedy Shriver National Institute on Child Health and Human Development under Vince Pozsgay, Ph.D., developing synthetic carbohydrate vaccine candidates and as a chemist at NIH’s Imaging Probe Development Center synthesizing novel imaging probes for targeting receptors, cells and tissues and for preclinical in vivo evaluations.
Dulcey earned his Bachelor of Science in chemistry from The Ohio State University, where he worked with Todd Lowary, Ph.D., on the synthesis of arabinofuranose analogs as inhibitors of Mycobacterium tuberculosis. Dulcey then earned his doctorate in organic chemistry from the University of Pennsylvania, where he worked under Virgil Percec, Ph.D., designing and synthesizing complex molecular dendrimers exhibiting biological functions.
Dulcey works on several collaborative endeavors in a multidisciplinary research environment, tackling metabolic disorders, central nervous system conditions, infectious diseases and autoimmune disorders, among others. He applies synthetic and medicinal chemistry as well as pharmacokinetic and pharmacodynamic principles in the design and synthesis of novel small molecules with drug-like properties. Some of Dulcey’s research interests include organic synthesis, carbohydrate chemistry, G protein–coupled receptors, functional selectivity and allosteric modulators.